AQST

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 49.5/100

📰 Latest News

Aquestive Therapeutics is a specialty pharmaceutical company leveraging its innovative PharmFilm technology to deliver differentiated therapies for neurological and other conditions, offering a unique value proposition in the drug delivery market with a focus on unmet medical needs and improved patient outcomes.

About AQST

Aquestive Therapeutics, Inc. focuses on developing and commercializing pharmaceutical products addressing unmet medical needs using its proprietary PharmFilm technology. The company's portfolio includes treatments for epilepsy, opioid dependence, chemotherapy-induced nausea, ADHD, and other neurological conditions.

Aquestive Therapeutics, Inc. Company Overview

Aquestive Therapeutics, Inc., founded in 2004 and headquartered in Warren, New Jersey, is a pharmaceutical company dedicated to identifying, developing, and commercializing differentiated products that address unmet medical needs. The company's core expertise lies in its proprietary PharmFilm technology, which enables the delivery of drugs through a thin, dissolvable film. This innovative approach offers several advantages over traditional dosage forms, including improved bioavailability, ease of administration, and enhanced patient compliance. Aquestive's commercial product portfolio includes Sympazan, an oral soluble film for Lennox-Gastaut syndrome; Suboxone, a sublingual film for opioid dependence; Zuplenz, an oral soluble film for chemotherapy-induced nausea; and Azstarys, a once-daily treatment for ADHD. The company is also developing a pipeline of proprietary product candidates, including Libervant, a buccal soluble film for seizures; Exservan, an oral soluble film for amyotrophic lateral sclerosis; AQST-108, a sublingual epinephrine film for conditions other than anaphylaxis; AQST-305, a sublingual octreotide film for acromegaly; AQST-109, an orally delivered epinephrine product for anaphylaxis; and KYNMOBI, a sublingual apomorphine film for Parkinson's disease. Aquestive's focus on innovative drug delivery and unmet medical needs positions it as a key player in the specialty pharmaceutical market.

Investment Thesis

Aquestive Therapeutics presents a compelling investment opportunity due to its innovative PharmFilm technology and a diverse portfolio of products targeting significant unmet medical needs. The company's focus on developing differentiated therapies with improved bioavailability and patient compliance offers a competitive advantage in the specialty pharmaceutical market. Key value drivers include the successful commercialization of existing products like Sympazan and Azstarys, as well as the potential approval and launch of pipeline candidates such as Libervant for seizures and AQST-109 for anaphylaxis. The company's gross margin of 60.3% demonstrates strong profitability potential. Upcoming catalysts include clinical trial results for AQST-109 and potential partnerships for its pipeline products. With a market cap of $0.29 billion, Aquestive offers significant upside potential as it executes its growth strategy and expands its market presence.

Key Financial Highlights

• Gross Margin of 60.3% indicates strong profitability potential for its marketed products.
• Market Cap of $0.29 billion suggests significant growth potential if pipeline products are successfully commercialized.
• Focus on PharmFilm technology provides a differentiated approach to drug delivery, potentially improving patient outcomes and compliance.
• Diverse product portfolio targeting multiple therapeutic areas reduces reliance on a single product.
• Proprietary pipeline of complex molecule products offers long-term growth opportunities.

Industry Context

Aquestive Therapeutics operates in the specialty pharmaceutical industry, which is characterized by a focus on developing and marketing innovative therapies for niche markets with unmet medical needs. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in drug delivery technologies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms. Aquestive differentiates itself through its proprietary PharmFilm technology, which offers advantages over traditional dosage forms. The global specialty pharmaceuticals market is projected to reach hundreds of billions of dollars in the coming years, providing ample growth opportunities for companies like Aquestive.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expansion of AQST-109 (oral epinephrine) for anaphylaxis: The anaphylaxis market represents a significant opportunity, with a growing need for improved emergency treatments. AQST-109, Aquestive's orally delivered epinephrine product candidate, has the potential to disrupt the market by offering a more convenient and patient-friendly alternative to traditional injectable epinephrine. Successful development and commercialization of AQST-109 could capture a substantial share of this market, estimated to be worth hundreds of millions of dollars annually, with potential launch in 2027.
• Commercialization of Libervant for seizures: Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures, addresses a critical unmet need for patients requiring rapid and convenient seizure control. The market for acute seizure treatments is substantial, and Libervant's unique delivery method could provide a competitive advantage. Approval and launch of Libervant would drive significant revenue growth for Aquestive, with potential peak sales estimated at over $100 million, with potential launch in 2026.
• Development of AQST-305 for acromegaly: AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly, offers a potential alternative to injectable octreotide, providing improved patient convenience and compliance. The acromegaly market is growing, driven by increasing awareness and diagnosis of the condition. Successful development and commercialization of AQST-305 could capture a portion of this market, with potential peak sales estimated at tens of millions of dollars annually. Timeline for launch is estimated to be 2028.
• Leveraging PharmFilm technology for new drug delivery applications: Aquestive's proprietary PharmFilm technology has the potential to be applied to a wide range of drugs and therapeutic areas. The company can explore partnerships with other pharmaceutical companies to develop new PharmFilm-based products, generating licensing revenue and expanding its market reach. This represents a significant long-term growth opportunity, with potential applications in various therapeutic areas. This is an ongoing opportunity.
• Geographic expansion into international markets: Aquestive's current commercial focus is primarily on the United States. Expanding into international markets, such as Europe and Asia, would significantly increase its market opportunity and revenue potential. This could be achieved through partnerships with local distributors or by establishing a direct sales presence in key markets. This is an ongoing opportunity.

Competitive Advantages

• Proprietary PharmFilm technology provides a differentiated drug delivery platform.
• Established commercial infrastructure for marketing and distributing specialty pharmaceutical products.
• Strong intellectual property protection for its products and technology.
• Focus on niche markets with unmet medical needs reduces competition.

Strengths

• Proprietary PharmFilm technology.
• Diverse product portfolio.
• Established commercial infrastructure.
• Focus on unmet medical needs.

Weaknesses

• Negative profit margin (-158.9%).
• Reliance on key products for revenue.
• Limited financial resources compared to larger pharmaceutical companies.
• Dependence on regulatory approvals for pipeline products.

Opportunities

• Expansion into new therapeutic areas.
• Geographic expansion into international markets.
• Partnerships with other pharmaceutical companies.
• Development of new PharmFilm-based products.

Threats

• Competition from larger pharmaceutical companies.
• Regulatory hurdles and delays.
• Patent expirations.
• Product liability claims.

What AQST Does

• Develop and commercialize pharmaceutical products using their proprietary PharmFilm technology.
• Market Sympazan for the treatment of Lennox-Gastaut syndrome.
• Market Suboxone for the treatment of opioid dependence.
• Market Zuplenz for the treatment of chemotherapy-induced nausea and vomiting.
• Market Azstarys for the treatment of attention deficit hyperactivity disorder (ADHD).
• Develop Libervant for the treatment of seizures.
• Develop Exservan for the treatment of amyotrophic lateral sclerosis (ALS).

Business Model

• Develop proprietary pharmaceutical products using PharmFilm technology.
• Manufacture and market these products directly or through partnerships.
• Generate revenue through product sales and licensing agreements.
• Focus on niche markets with unmet medical needs.

Key Customers

• Patients suffering from Lennox-Gastaut syndrome (Sympazan).
• Patients suffering from opioid dependence (Suboxone).
• Patients undergoing chemotherapy and experiencing nausea and vomiting (Zuplenz).
• Patients with attention deficit hyperactivity disorder (ADHD) (Azstarys).
• Patients with seizures (Libervant - in development).

Competitors

• Arvinas, Inc. (ARVN): Focuses on protein degradation therapeutics.
• Anavex Life Sciences Corp. (AVXL): Develops therapeutics for neurodegenerative diseases.
• DarioHealth Corp. (DRIO): Offers digital health solutions for chronic conditions.
• Emergent BioSolutions Inc. (EBS): Specializes in biodefense and emerging infectious diseases.
• Erasca, Inc. (ERAS): Focuses on developing therapies for cancer.

Catalysts

• Upcoming: Clinical trial results for AQST-109 (oral epinephrine) in 2026.
• Upcoming: Potential FDA approval and launch of Libervant for seizures in 2026.
• Ongoing: Continued commercialization and market penetration of existing products (Sympazan, Suboxone, Zuplenz, Azstarys).
• Ongoing: Development and advancement of pipeline products (AQST-305, Exservan, KYNMOBI).
• Ongoing: Potential partnerships and licensing agreements for PharmFilm technology.

Risks

• Potential: Failure to obtain regulatory approvals for pipeline products.
• Potential: Competition from existing and new therapies.
• Potential: Product liability claims.
• Ongoing: Dependence on key products for revenue.
• Ongoing: Negative profit margin and limited financial resources.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Drug Manufacturers - Specialty & Generic

Browse More

Next Steps